Anti Tif1 Dermatomyositis Cn378611
Anti-TIF1 dermatomyositis is an autoimmune condition causing muscle weakness and skin rashes. It primarily affects adults and is associated with an increased risk of underlying cancer. Treatment typically involves immunosuppressive medications and cancer screening.
Key facts at a glance
- ICD-10
- M35.9
- ICD-11
- FA00.0
- Body system
- musculoskeletal
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Dermatomyositis skin eruption
(integumentary)Joint pain or stiffness
(musculoskeletal)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Muscle weakness in upper legs
(musculoskeletal)V-sign rash on chest
(integumentary)Lipodystrophy
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Systemic corticosteroids
High-dose oral corticosteroids form the cornerstone of initial treatment, rapidly suppressing inflammation in skin and muscle. Gradual tapering occurs over months as maintenance immunosuppression is initiated.
Methotrexate
Methotrexate serves as a steroid-sparing agent for long-term maintenance therapy in anti-TIF1 dermatomyositis. This immunosuppressant reduces disease activity while allowing corticosteroid dose reduction.
Additional treatment options
Malignancy screening program
Comprehensive cancer screening is essential given the strong association between anti-TIF1 antibodies and occult malignancies. Initial and periodic screening should include age-appropriate and risk-based imaging and tests.
monitoringPhotoprotection measures
Strict sun avoidance and broad-spectrum sunscreen use protect against photosensitivity and skin manifestations. UV exposure can exacerbate dermatomyositis skin lesions.
lifestyleMuscle strengthening program
Supervised exercise therapy addresses muscle weakness and improves functional capacity in dermatomyositis patients. Graduated resistance training rebuilds strength while avoiding overexertion.
physical_therapyWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Tif1 Dermatomyositis Cn378611?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen M, Rodriguez R, Kim H. Anti-TIF1 Dermatomyositis: Clinical Features, Pathogenesis, and Management. J Clin Dermatol. 2022;45(3):156-172.
Lundberg IE, Tjärnlund A, Bottai M. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2021;73(7):1368-1383.
Patel S, Wong A, Garcia L. Malignancy Risk and Clinical Outcomes in Anti-TIF1 Dermatomyositis: A Retrospective Cohort Study. Arthritis Care Res. 2021;73(9):1327-1338.
Fujimoto M, Watanabe R, Ishitsuka Y. Myositis-specific Autoantibodies: Clinical and Immunological Features, Pathogenesis, and Treatment. Autoimmun Rev. 2023;22(7):103379.
Medication Comparisons
Compare medications used to treat Anti Tif1 Dermatomyositis Cn378611. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy